Special Issue "Cancer Epigenetics"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2013)
Dr. Taiping Chen
The University of Texas MD Anderson Cancer Center, 1808 Park Road 1C, P.O. Box 389, Unit Number: 0116, Smithville, TX 78957, USA
Interests: DNA methylation; histone modifications; genomic imprinting; mammalian development; cancer epigenetics
The role of genetic alterations in cancer is well established. It is generally accepted, however, that genetic changes alone do not fully account for malignancy. Growing evidence has indeed implicated the involvement of epigenetic alterations in cancer. Unlike irreversible genetic mutations, epigenetic alterations are potentially reversible, which makes epigenetic therapy (modulation of epigenetic states) an appealing strategy for cancer treatment. Alterations of epigenetic marks could also serve as biomarkers for diagnosis, prognosis, and responses to therapies. To realize the potential of epigenetics in clinical applications, it is essential to understand the fundamental aspects of cancer epigenetics. For this special issue of Cancers dedicated to cancer epigenetics, we invite manuscripts that address various epigenetic mechanisms, such as DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs, in cancer. We are particularly interested in manuscripts that aim to document epigenetic alterations in cancer, elucidate the mechanisms underlying such alterations, and understand the roles of such alterations in the initiation and progression of cancer.
Dr. Taiping Chen
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- DNA methylation
- histone modifications
- genomic imprinting
- mammalian development
- cancer epigenetics
Article: Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells
Cancers 2013, 5(2), 334-356; doi:10.3390/cancers5020334
Received: 5 February 2013; in revised form: 23 March 2013 / Accepted: 26 March 2013 / Published: 3 April 2013| Download PDF Full-text (1358 KB) | Download XML Full-text | Supplementary Files
Cancers 2013, 5(2), 430-461; doi:10.3390/cancers5020430
Received: 28 February 2013; in revised form: 3 April 2013 / Accepted: 8 April 2013 / Published: 15 April 2013| Download PDF Full-text (954 KB) | Download XML Full-text
Cancers 2013, 5(2), 676-713; doi:10.3390/cancers5020676
Received: 21 March 2013; in revised form: 22 May 2013 / Accepted: 24 May 2013 / Published: 5 June 2013| Download PDF Full-text (603 KB) | Download XML Full-text
Cancers 2013, 5(3), 786-814; doi:10.3390/cancers5030786
Received: 26 March 2013; in revised form: 16 May 2013 / Accepted: 29 May 2013 / Published: 25 June 2013| Download PDF Full-text (1678 KB) | Download XML Full-text
Review: Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Cancers 2013, 5(3), 919-942; doi:10.3390/cancers5030919
Received: 22 April 2013; in revised form: 3 July 2013 / Accepted: 12 July 2013 / Published: 25 July 2013| Download PDF Full-text (371 KB) | Download XML Full-text
Cancers 2013, 5(3), 998-1019; doi:10.3390/cancers5030998
Received: 26 June 2013; in revised form: 16 July 2013 / Accepted: 24 July 2013 / Published: 9 August 2013| Download PDF Full-text (783 KB) | Download XML Full-text
Last update: 25 September 2012